These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27329552)

  • 21. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study.
    Roberts JA; Boots R; Rickard CM; Thomas P; Quinn J; Roberts DM; Richards B; Lipman J
    J Antimicrob Chemother; 2007 Feb; 59(2):285-91. PubMed ID: 17135183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.
    Wang JY; Hsueh PR; Jan IS; Lee LN; Liaw YS; Yang PC; Luh KT
    Thorax; 2006 Oct; 61(10):903-8. PubMed ID: 16809417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of guideline-concordant antibiotics and macrolide/β-lactam combinations in 3203 patients hospitalized with pneumonia: prospective cohort study.
    Asadi L; Eurich DT; Gamble JM; Minhas-Sandhu JK; Marrie TJ; Majumdar SR
    Clin Microbiol Infect; 2013 Mar; 19(3):257-64. PubMed ID: 22404691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trimethoprim/sulfamethoxazole resistance in urinary tract infections.
    Guneysel O; Onur O; Erdede M; Denizbasi A
    J Emerg Med; 2009 May; 36(4):338-41. PubMed ID: 18325714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early Mortality during Initial Treatment of Tuberculosis in Patients Co-Infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-Year Retrospective Cohort Study (2006-2013).
    Bigna JJ; Noubiap JJ; Agbor AA; Plottel CS; Billong SC; Ayong AP; Koulla-Shiro S
    PLoS One; 2015; 10(7):e0132394. PubMed ID: 26214516
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
    Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
    Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis.
    Webster D; Long R; Shandro C; Pettipas J; Leblanc J; Davidson R; Fanning A
    Int J Tuberc Lung Dis; 2010 Feb; 14(2):217-22. PubMed ID: 20074414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of broad-spectrum antibiotics in French EDs: different trends for third-generation cephalosporins and fluoroquinolones.
    Batard E; Vibet MA; Lemarchand C; Navas D; Lepelletier D; Potel G; Montassier E;
    Eur J Emerg Med; 2017 Jun; 24(3):189-195. PubMed ID: 26426738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
    Deal EN; Micek ST; Reichley RM; Ritchie DJ
    Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emergence of quinolone resistance in the microbiota of hospitalized patients treated or not with a fluoroquinolone.
    de Lastours V; Chau F; Roy C; Larroque B; Fantin B
    J Antimicrob Chemother; 2014 Dec; 69(12):3393-400. PubMed ID: 25063781
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system.
    McFarland LV; Clarridge JE; Beneda HW; Raugi GJ
    Clin Infect Dis; 2007 Nov; 45(9):1141-51. PubMed ID: 17918075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Moxifloxacin Use and Its Association on the Diagnosis of Pulmonary Tuberculosis in An Inner City Emergency Department.
    Rush B; Wormsbecker A; Stenstrom R; Kassen B
    J Emerg Med; 2016 Mar; 50(3):371-5. PubMed ID: 26416134
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Moxifloxacin plus standard first-line therapy in the treatment of pulmonary tuberculosis: A meta-analysis.
    Chen Z; Liang JQ; Wang JH; Feng SS; Zhang GY
    Tuberculosis (Edinb); 2015 Jul; 95(4):490-6. PubMed ID: 25964137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital.
    Liu CH; Yang N; Wang Q; Hu YL; Li L; Zhang GY; Zhu B
    Respirology; 2011 Aug; 16(6):918-25. PubMed ID: 21564401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Retrospective Cohort of Extended-Infusion Piperacillin-Tazobactam (RECEIPT) study: a multicenter study.
    Yost RJ; Cappelletty DM;
    Pharmacotherapy; 2011 Aug; 31(8):767-75. PubMed ID: 21923603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are first-generation cephalosporins obsolete? A retrospective, non-inferiority, cohort study comparing empirical therapy with cefazolin versus ceftriaxone for acute pyelonephritis in hospitalized patients.
    Hobbs AL; Shea KM; Daley MJ; Huth RG; Jaso TC; Bissett J; Hemmige V
    J Antimicrob Chemother; 2016 Jun; 71(6):1665-71. PubMed ID: 26983859
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Appropriate use of fluoroquinolones in children.
    Principi N; Esposito S
    Int J Antimicrob Agents; 2015 Apr; 45(4):341-6. PubMed ID: 25726705
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.
    Ng TM; Teng CB; Lye DC; Apisarnthanarak A
    Infect Control Hosp Epidemiol; 2014 Jan; 35(1):49-55. PubMed ID: 24334798
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
    Gaba PD; Haley C; Griffin MR; Mitchel E; Warkentin J; Holt E; Baggett P; Sterling TR
    Arch Intern Med; 2007 Nov; 167(21):2317-22. PubMed ID: 18039990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.